NM X1
Alternative Names: NM-X1Latest Information Update: 19 Jul 2022
At a glance
- Originator NovoMedix
- Class Antineoplastics; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Interleukin 11 inhibitors; MTOR protein inhibitors; STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Lung cancer; Pancreatic cancer; Sarcoma; Triple negative breast cancer
Most Recent Events
- 19 Jul 2022 Preclinical trials in Colorectal cancer in USA (PO) before July 2022(NovoMedix website, July 2022)
- 19 Jul 2022 Preclinical trials in Lung cancer in USA (PO) before July 2022(NovoMedix website, July 2022)
- 19 Jul 2022 Preclinical trials in Pancreatic cancer in USA (PO) before July 2022(NovoMedix website, July 2022)